Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5248290 | 0.96 | TSHR (0.34) | TSHRKDM4EALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL4379120 | 0.82 | TSHR (0.36) | TSHRKDM4EALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL11656664 | 0.82 | TSHR (0.36) | TSHRKDM4EALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL31325992 | 0.80 | TSHR (0.44) | TSHRKDM4EALDH1A1HSD17B10MGAM | |
| Hydrochloric Acid SCHEMBL11658513 | 0.80 | KDM4E (0.38) | TSHRKDM4EALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL11307490 | 0.79 | TSHR (0.37) | TSHRKDM4EALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL25092225 | 0.79 | CTSK (0.31) | KDM4EALDH1A1CYP1A2 | |
| SCHEMBL11727365 | 0.79 | TSHR (0.33) | TSHRKDM4EALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL11730596 | 0.76 | TSHR (0.34) | TSHRKDM4EALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL8892122 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1631355-B1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | ALLERGAN INC (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-1817033-B1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALLERGAN INC (US) | 2009-11-18 | — | — | EP | disclosed |
| EP-1722795-B1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | ALLERGAN INC (US) | 2008-05-07 | — | — | EP | disclosed |
| US-7326716-B2 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1817033-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | Allergan, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| US-7179820-B2 | Piperidinyl prostaglandin E analogs | ALLERGAN, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1722795-A1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | Allergan, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2006058080-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALLERGAN, INC. (US) | 2006-06-01 | — | — | WO | disclosed |
| EP-1631355-A1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | Allergan, Inc. (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6977260-B2 | administering to an animal having ocular hypertension a piperidynly analog; a container adapted to dispense the ophthalmic solution in a metered form | ALLERGAN, INC. (US) | 2005-12-20 | — | — | US | disclosed |
| WO-2005072735-A1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | ALLERGAN, INC. (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050171062-A1 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050164990-A1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | ALLERGAN, INC. | 2005-07-28 | — | — | US | disclosed |
| WO-2004108215-A1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | ALLERGAN, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040248854-A1 | Piperidinyl prostaglandin E analogs | ALLERGAN, INC. | 2004-12-09 | — | — | US | disclosed |
| US-4234720-A | Prostaglandin derivatives | ABBOTT LABORATORIES (US) | 1980-11-18 | — | — | US | disclosed |
| US-4022794-A | VASODILATION | MERCK & CO., INC. (US) | 1977-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050164990-A1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | PTGIR, PTGDR, PTGER1 | TSHR 1262/4885KDM4E 1361/4885ALDH1A1 569/4885 |
| US-20050171062-A1 | Treatment of inflammatory bowel disease | SLC10A2, GUCY1B1, PTGER1 | TSHR 2519/4885KDM4E 2004/4885ALDH1A1 594/4885 |
| US-20040248854-A1 | Piperidinyl prostaglandin E analogs | PTGIR, PTGER1, PTGS1 | TSHR 1976/4885KDM4E 1141/4885ALDH1A1 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.